We expect continued choppy waters in healthcare deals for two primary reasons: 1. Functional reductions in Medicare Advantage reimbursement rates, and 2. A growing political consensus against private equity in healthcare.
Four reasons why our CEO believes transaction volume will be up in 2024 relative to the prior year.
This article was originally published in Forbes. Fortune 500 companies receive real-time feedback regarding their market value thanks to the stock market. Unfortunately, private mid-market businesses don’t have that luxury, with many owners totally in the dark. Of course you often hear whispered “country club” multiples, but they often are exaggerated, reflect a strong selection…
This article was originally published in Forbes. It started with a dream decades ago and through hard work and determination, you built a thriving business. Given your limited budget, you learned on the fly how to create and refine your product, how to market it, and how to build and manage a team. You’ve achieved…
This article was originally published in Forbes. Private equity’s (PE) playbook for creating investment value is relatively basic and straightforward (though not necessarily easy). Building on my prior article, The Alchemy of Private Equity Explained, this article delves into the strategies and tactics used by PE investors to boost EBITDA (Earnings before Interest, Taxes, Depreciation,…
